Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05389722 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT05389722 is a Phase 1 study of Healthy Volunteers that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05389722, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

Conditions Studied

Interventions

  • DRUG Rifampin
  • DRUG Itraconazole
  • DRUG Rosuvastatin
  • DRUG CC-92480
  • DRUG Digoxin

Study Locations (1)

Texas

  • Covance Clinical Research Unit - Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-06-09
Est. Completion 2022-11-12
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT05389722

The ClinicalTrials.gov registry entry for NCT05389722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 5 interventions - of which Rifampin is the first listed.

NCT05389722 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05389722 about?

NCT05389722 is a clinical study titled "A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants". The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after coadministration with CC-92480 in healthy participants.

What is the current status of trial NCT05389722?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-06-09. Estimated completion is 2022-11-12.

What conditions does trial NCT05389722 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT05389722?

The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), Rosuvastatin (DRUG), CC-92480 (DRUG), Digoxin (DRUG).

Who is sponsoring clinical trial NCT05389722?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05389722 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.